VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 75 filers reported holding VIRIDIAN THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,161,557 | -36.2% | 401,666 | -1.0% | 0.00% | -50.0% |
| Q2 2023 | $9,655,529 | +2.3% | 405,865 | +9.4% | 0.00% | 0.0% |
| Q1 2023 | $9,436,356 | -10.7% | 370,926 | +2.6% | 0.00% | 0.0% |
| Q4 2022 | $10,564,936 | +88.8% | 361,689 | +32.6% | 0.00% | +100.0% |
| Q3 2022 | $5,595,000 | +98.2% | 272,811 | +11.8% | 0.00% | 0.0% |
| Q2 2022 | $2,823,000 | +170.4% | 243,956 | +331.9% | 0.00% | – |
| Q1 2022 | $1,044,000 | -11.0% | 56,487 | -4.8% | 0.00% | – |
| Q4 2021 | $1,173,000 | +105.8% | 59,328 | +71.2% | 0.00% | – |
| Q3 2021 | $570,000 | -1.0% | 34,651 | +10.1% | 0.00% | – |
| Q2 2021 | $576,000 | – | 31,467 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $68,684,566 | 13.41% |
| COMMODORE CAPITAL LP | 2,189,659 | $55,704,925 | 8.48% |
| Fairmount Funds Management LLC | 1,369,623 | $34,843,209 | 5.99% |
| Paradigm Biocapital Advisors LP | 2,085,698 | $53,060,157 | 5.03% |
| Octagon Capital Advisors LP | 1,185,000 | $30,146,400 | 4.34% |
| Logos Global Management LP | 950,000 | $24,168,000 | 3.46% |
| TCG Crossover Management, LLC | 663,610 | $16,882,238 | 3.29% |
| ACUTA CAPITAL PARTNERS, LLC | 168,000 | $4,273,920 | 3.15% |
| Vivo Capital, LLC | 1,678,207 | $42,693,586 | 2.96% |
| TANG CAPITAL MANAGEMENT LLC | 692,925 | $17,628,012 | 2.63% |